FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027805131> ?p ?o ?g. }

• W2027805131 endingPage "445" @default.
• W2027805131 startingPage "438" @default.
• W2027805131 abstract "Thus far, peptide vaccines used to stimulate tumor-specific immune responses in patients with melanoma have been largely unsuccessful. Granulocyte-macrophage colony-stimulating factor and interleukin-2 are immune-potentiating cytokines that have improved vaccine responses in preclinical models. We hypothesized that higher doses of granulocyte-macrophage colony-stimulating factor and addition of low-dose interleukin-2 might augment responses to vaccine antigens. Patients with resected stage II, III, or IV melanoma were treated with vaccines containing three melanoma-associated peptides [MART-1a, gp100(207–217), and survivin], along with 300 or 500 mcg granulocyte-macrophage colony-stimulating factor in Montanide ISA. Cohorts of patients received low-dose subcutaneous interleukin-2 on days 7–20 after vaccination. Induction of a response was defined as either doubling of cytotoxic T lymphocyte frequency from baseline or increase in frequency from undetectable (<0.05%) to detectable. Leukocyte subsets and plasma cytokines were analyzed before and after vaccination. Cytotoxic T lymphocyte responses to MART-1a, gp100(207–217), and survivin were induced in 11, 16, and 14 of 19 patients, respectively. Responses were not higher in patients receiving 500 mcg granulocyte-macrophage colony-stimulating factor or low-dose interleukin-2 than in patients receiving 300 mcg granulocyte-macrophage colony-stimulating factor only. Interleukin-2 treatment (in nine patients) led to increases in natural killer cells and T regulatory cells compared with no interleukin-2 treatment (nine patients). Multiple plasma cytokines were transiently induced during vaccination. Neither increasing the dose of granulocyte-macrophage colony-stimulating factor nor addition of low-dose interleukin-2 resulted in an increase in the frequency of vaccine-specific cytotoxic T lymphocytes to a melanoma peptide vaccine. The increase in T regulatory cells associated with interleukin-2 treatment suggests that interleukin-2 may be immunosuppressive in this setting." @default.
• W2027805131 created "2016-06-24" @default.
• W2027805131 creator A5000164383 @default.
• W2027805131 creator A5006194799 @default.
• W2027805131 creator A5012709955 @default.
• W2027805131 creator A5029846347 @default.
• W2027805131 creator A5032917850 @default.
• W2027805131 creator A5054678780 @default.
• W2027805131 creator A5067707171 @default.
• W2027805131 creator A5082661564 @default.
• W2027805131 creator A5082719040 @default.
• W2027805131 date "2011-10-01" @default.
• W2027805131 modified "2023-09-23" @default.
• W2027805131 title "Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine" @default.
• W2027805131 cites W1618457534 @default.
• W2027805131 cites W1986438546 @default.
• W2027805131 cites W2015787544 @default.
• W2027805131 cites W2016671320 @default.
• W2027805131 cites W2025240311 @default.
• W2027805131 cites W2034164043 @default.
• W2027805131 cites W2035591127 @default.
• W2027805131 cites W2038465532 @default.
• W2027805131 cites W2052626082 @default.
• W2027805131 cites W2057427371 @default.
• W2027805131 cites W2073852192 @default.
• W2027805131 cites W2095224835 @default.
• W2027805131 cites W2097393755 @default.
• W2027805131 cites W2104525960 @default.
• W2027805131 cites W2106414148 @default.
• W2027805131 cites W2108108310 @default.
• W2027805131 cites W2139863489 @default.
• W2027805131 cites W2148523692 @default.
• W2027805131 cites W4254116863 @default.
• W2027805131 doi "https://doi.org/10.1097/cmr.0b013e32834640c0" @default.
• W2027805131 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21697748" @default.
• W2027805131 hasPublicationYear "2011" @default.
• W2027805131 type Work @default.
• W2027805131 sameAs 2027805131 @default.
• W2027805131 citedByCount "17" @default.
• W2027805131 countsByYear W20278051312012 @default.
• W2027805131 countsByYear W20278051312013 @default.
• W2027805131 countsByYear W20278051312014 @default.
• W2027805131 countsByYear W20278051312015 @default.
• W2027805131 countsByYear W20278051312016 @default.
• W2027805131 countsByYear W20278051312017 @default.
• W2027805131 countsByYear W20278051312019 @default.
• W2027805131 countsByYear W20278051312020 @default.
• W2027805131 crossrefType "journal-article" @default.
• W2027805131 hasAuthorship W2027805131A5000164383 @default.
• W2027805131 hasAuthorship W2027805131A5006194799 @default.
• W2027805131 hasAuthorship W2027805131A5012709955 @default.
• W2027805131 hasAuthorship W2027805131A5029846347 @default.
• W2027805131 hasAuthorship W2027805131A5032917850 @default.
• W2027805131 hasAuthorship W2027805131A5054678780 @default.
• W2027805131 hasAuthorship W2027805131A5067707171 @default.
• W2027805131 hasAuthorship W2027805131A5082661564 @default.
• W2027805131 hasAuthorship W2027805131A5082719040 @default.
• W2027805131 hasConcept C126322002 @default.
• W2027805131 hasConcept C154317977 @default.
• W2027805131 hasConcept C202751555 @default.
• W2027805131 hasConcept C203014093 @default.
• W2027805131 hasConcept C2776694085 @default.
• W2027805131 hasConcept C2777371288 @default.
• W2027805131 hasConcept C2777478134 @default.
• W2027805131 hasConcept C2777701055 @default.
• W2027805131 hasConcept C2777767877 @default.
• W2027805131 hasConcept C2777983669 @default.
• W2027805131 hasConcept C2778690821 @default.
• W2027805131 hasConcept C55493867 @default.
• W2027805131 hasConcept C71924100 @default.
• W2027805131 hasConcept C74172505 @default.
• W2027805131 hasConcept C86803240 @default.
• W2027805131 hasConcept C8891405 @default.
• W2027805131 hasConceptScore W2027805131C126322002 @default.
• W2027805131 hasConceptScore W2027805131C154317977 @default.
• W2027805131 hasConceptScore W2027805131C202751555 @default.
• W2027805131 hasConceptScore W2027805131C203014093 @default.
• W2027805131 hasConceptScore W2027805131C2776694085 @default.
• W2027805131 hasConceptScore W2027805131C2777371288 @default.
• W2027805131 hasConceptScore W2027805131C2777478134 @default.
• W2027805131 hasConceptScore W2027805131C2777701055 @default.
• W2027805131 hasConceptScore W2027805131C2777767877 @default.
• W2027805131 hasConceptScore W2027805131C2777983669 @default.
• W2027805131 hasConceptScore W2027805131C2778690821 @default.
• W2027805131 hasConceptScore W2027805131C55493867 @default.
• W2027805131 hasConceptScore W2027805131C71924100 @default.
• W2027805131 hasConceptScore W2027805131C74172505 @default.
• W2027805131 hasConceptScore W2027805131C86803240 @default.
• W2027805131 hasConceptScore W2027805131C8891405 @default.
• W2027805131 hasIssue "5" @default.
• W2027805131 hasLocation W20278051311 @default.
• W2027805131 hasLocation W20278051312 @default.
• W2027805131 hasOpenAccess W2027805131 @default.
• W2027805131 hasPrimaryLocation W20278051311 @default.
• W2027805131 hasRelatedWork W1494014013 @default.
• W2027805131 hasRelatedWork W1992114636 @default.
• W2027805131 hasRelatedWork W2024535659 @default.
• W2027805131 hasRelatedWork W2092305714 @default.

• next